President and Chief Executive Officer
Steven Lo is our Chief Executive Officer and member of the board of directors. Steve was previously the chief commercial officer at Puma Biotechnology where he built the commercial operations infrastructure and team to launch the company’s first product, NERLYNX®, in the United States while leading the execution of global licensing agreements for rest of world. Previously, he was senior vice president and chief commercial officer at Corcept Therapeutics. At Corcept, Mr. Lo formed the commercial organization to launch the company’s first product, Korlym®, an endocrine specialty medication for a rare orphan disease (Cushing’s syndrome) and also was responsible for the corporate strategy and development of the company’s oncology franchise. Earlier in his career, he spent 13 years at Genentech in increasingly responsible roles in market access, sales and marketing, ultimately serving as franchise head, Endocrinology. He started his career in the pharmaceutical industry at AstraZeneca after holding roles in finance and operations at Kaiser Permanente. Mr. Lo holds a master’s in health administration from the University of Southern California and a B.S. in microbiology from the University of California, Davis.
Chief Financial Officer
Christine Matthews has served as our Chief Financial Officer, responsible for Finance, Accounting, Tax and Treasury, since May 2020 and as VP and Corporate Controller of the Company since January 2019. She has over 20 years of broad leadership experience in finance and accounting. Prior to joining Zosano, she served as an accounting and financial consultant with RGP, a professional services company. Her past positions include Senior Director of Financial Planning & Analysis at Cepheid, a leading molecular diagnostic company (acquired by Danaher), supporting North America commercial operations, as well as Group Director of Finance at Cadence Design Systems. Ms. Matthews began her career with Arthur Andersen, LLP and holds a B.S. in Business Administration with an Emphasis in Accounting from the University of Colorado at Boulder.
Donald Kellerman, PharmD
Vice President, Clinical Development and Medical Affairs
Dr. Kellerman has served as our Vice President of Clinical Operations since July 2015. Prior to joining Zosano, Dr. Kellerman served as Senior Vice President of Clinical Development & Regulatory Affairs at Tonix Pharmaceuticals. Previously, Dr. Kellerman served as Senior Vice President of Clinical Development & Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.) for five years. Dr. Kellerman also held the position of Senior Vice President of Development at Inspire Pharmaceuticals, Inc. for nine years, where he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project management and biostatistics. He also led groups responsible for running several clinical programs in the respiratory, ophthalmology and cardiovascular areas. In addition, Dr. Kellerman has served in various clinical and project leadership positions at Glaxo Wellcome, Sepracor, Inc., and E.R. Squibb and Sons, Inc. He has more than 25 years of experience in the development of prescription pharmaceuticals and has lead- or co-authored more than 80 publications. Dr. Kellerman holds Doctor of Pharmacy and Bachelor of Science degrees from the College of Pharmacy at the University of Minnesota.
Mahmoud Ameri, PhD
Vice President, Research and Development
Dr. Ameri has served as our Vice President of Research and Development since 2015. Dr. Ameri is one of the first employees at Zosano Pharma and has over 20 years of experience in drug delivery and pharmaceutical development. Prior to Zosano, he worked at PowderJect, Johnson and Johnson, and Alza were he co-invented and developed the transdermal microneedle technology. He has been awarded 12 United States Patents for the transdermal microneedle technology and has lead or co-authored more than 20 publications. Dr. Ameri received his Ph.D. from the School of Pharmacy at the University of Manchester in the United Kingdom.
Vice President, Technical Operations
Lu Liu has served as our Vice President of Technical Operations since Feb 2019 and as a Senior Director of Manufacturing and Supply Chain since August 2015. She oversees the technical development of M207 and building a supply chain ready for commercialization. Ms. Liu has over 25 years of experience in managing manufacturing and supply chain operations and CMC related activities for small molecules, implantable biomaterials, combination drug products, and devices. Prior to joining Zosano, Ms. Liu held progressive roles at Biomet, Johnson and Johnson and DePuy Spine. She has a BS in Chemical Engineering from the University of California, Davis.
Vice President, Quality Assurance & Regulatory Affairs
Gregory Meyer is our Vice President of Quality Assurance and Regulatory Affairs. Greg has previously been VP of QA/RA at commercial biologics company Skye Biologics, and drug-device combination company BioQ Pharma. While at BioQ Pharma he was responsible for submissions achieving approval and commercialization of IV drugs in the EU, Australia, the Middle East and North Africa. He was Head of Quality at Stem CentRx helping them achieve GMP compliance and IND acceptance for a novel cancer stem-cell targeted ADC drug leading to their acquisition by AbbVie. He also held roles at Chiron and Aradigm. Greg attended St. John’s University and Reed College and has certifications as an RAC in Regulatory Affairs from the Regulatory Affairs Professionals Society, a CQA in Quality Auditing from the American Society for Quality, and a CTBS in Tissue Banking from the American Association of Tissue Banks.
Vice President, Corporate Controller
Kristina Warga has served as our Vice President and Corporate Controller since 2020. She has over 25 years of extensive experience in finance and accounting, across multiple industries and geographies. Prior to joining Zosano, Ms. Warga held positions of increasing responsibility at Bio-Rad Laboratories, General Dynamics, and Arthur Andersen LLP. She holds a B.S. in Accounting from Clarkson University.